More and more branded drugs seem to be facing generic competition. The impact might not be so positive for Big Pharma giants, but this can be a serious victory for consumers and patients who…
There is great opportunity in healthcare. There is also quite a lot of risk. Politicians and consumers alike want lower drug prices. Patients want the best of the best options for devices, monitoring, and…
Pfizer released better-than-expected fourth-quarter financial results and guidance before the markets opened on Tuesday.
Pfizer is scheduled to release its fourth-quarter financial results before the markets open on Tuesday. Consensus estimates call for modest year-over-year growth.
The January 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The January 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
AbbVie shares retreated after it released disappointing fourth-quarter financial results before the markets opened on Friday.
Bristol-Myers Squibb reported better-than-expected quarterly results before the markets opened on Thursday.
In the fourth quarter of last year, the number of uninsured Americans reached the highest rate since 2014, according to a new research study by Gallup.
Editas Medicine shares were crushed on Tuesday after the company announced that its president and chief executive, Katrine Bosley, would be stepping down from these roles effective March 1.
Johnson & Johnson released better-than-expected fourth-quarter financial results before the markets opened on Tuesday.
Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result from this committee was mixed, it seems to be a case of sell the…
Immunomedics shares were crushed on Friday after the firm received disappointing news from the FDA on its breast cancer treatment.
Spectrum Pharmaceuticals on Thursday after the firm announced that it would be selling its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma.
The December 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
